SNSW(SH:688117) Zheng Quan Zhi Xing·2025-06-19 10:22Core Viewpoint - Chengdu Sanno Biological Technology Co., Ltd. expects significant growth in net profit for the first half of 2025, driven by market expansion and increased sales efforts in the peptide industry [1][2]. Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company between 77.03 million yuan and 102.36 million yuan, representing an increase of 253.54% to 332.10% compared to the previous year [1]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 77.35 million yuan and 94.53 million yuan, reflecting a year-on-year increase of 304.49% to 394.38% [1][2]. - For reference, the net profit for the same period last year was 21.79 million yuan, with a net profit of 19.12 million yuan after deducting non-recurring gains and losses [1]. Reasons for Performance Change - The company is closely following the development trends in the peptide industry and is actively expanding its marketing efforts both domestically and internationally, which has significantly boosted net profit [2].